venadaparib
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 29, 2017 (NCT03317743)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07269158 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Yonsei University |
| NCT05202912 | Phase 1 | Jan 16, 2022 | IlDong Pharmaceutical Co Ltd |
| NCT04725994 | Phase 1 | Jun 28, 2021 | IlDong Pharmaceutical Co Ltd |
| NCT04174716 | Phase 1/Phase 2 (Phase 2) | Nov 6, 2019 | IlDong Pharmaceutical Co Ltd |
| NCT03317743 | Phase 1 | Aug 29, 2017 | IlDong Pharmaceutical Co Ltd, National OncoVenture |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IlDong Pharmaceutical Co Ltd | For profit | 4 | 3 | 2 | 2017 |
| National OncoVenture | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1